H.C. Wainwright downgrades Crescent Biopharma stock rating to neutral

Investing.com - H.C. Wainwright downgraded Crescent Biopharma Inc (NASDAQ:CBIO) to Neutral from Buy, citing less compelling competitive positioning for the company’s CR-001 candidate following recent clinical data. The stock currently trades at $20.65 with a market cap of $686 million, and according to InvestingPro analysis, appears overvalued relative to its Fair Value estimate. Despite the downgrade, shares have surged 45% over the past six months and 74% year-to-date.

The firm’s prior rating was based on CR-001 as a fast follower to Summit and Akeso’s ivonescimab, with similar PD-1 x VEGF biology. The original thesis assumed ivonescimab could displace Keytruda in the market.

H.C. Wainwright said it is harder to support the same valuation after Merck & Co. and Kelun’s sacituzumab tirumotecan plus pembrolizumab regimen showed a stronger efficacy profile than ivonescimab in first-line non-small cell lung cancer. Sac-TMT plus pembro reduced the risk of progression or death by 65% versus pembro alone, while ivonescimab reduced it by 49% versus pembro in HARMONi-2.

Sac-TMT generated a response rate of 70.2% versus 42.0% for pembro, compared with 50.0% versus 38.5% for ivonescimab. The firm noted that pembro control arms were nearly identical on median progression-free survival at 5.7 months in OptiTROP-Lung05 and 5.82 months in HARMONi-2.Other analysts remain more optimistic, with price targets ranging from $22 to $35. InvestingPro Tips highlight that while the company holds more cash than debt on its balance sheet, it is not expected to be profitable this year. For investors seeking deeper insights, InvestingPro offers 7 additional exclusive tips, plus comprehensive Pro Research Reports covering CBIO and 1,400+ other US equities.

H.C. Wainwright removed its price target on Crescent Biopharma with the downgrade. The firm said survival data remain immature for both regimens, but sac-TMT already shows a favorable overall survival trend with a hazard ratio of 0.55.

In other recent news, Crescent Biopharma has announced that data from its ASCEND study will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. The ASCEND study is a global Phase 1/2 clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in patients with multiple solid tumor types. Meanwhile, H.C. Wainwright has adjusted its price target for Crescent Biopharma to $22, down from $25, but continues to maintain a Buy rating. The company recently dosed the first patient in the ASCEND trial and anticipates proof-of-concept data in the first quarter of 2027. Additionally, Crescent Biopharma plans to initiate a Phase 1/2 combination trial of CR-001 with an antibody-drug conjugate in the second half of 2026, with initial data expected by the end of 2027. These developments reflect ongoing progress in Crescent Biopharma’s clinical trials and strategic planning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.